SHARLET GEEVARUGHESE: Open Payments
NPI 1487037099 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,161 in 29 payments from 14 companies in 2025. Trend: 2023 $1,511 · 2024 $547 · 2025 $1,161
Food & beverage: $1,009Education: $152
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $233 |
| Janssen Biotech, Inc. | 7 | $210 |
| QOL Medical, LLC | 2 | $137 |
| Madrigal Pharmaceuticals | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $110 |
| Ardelyx, Inc. | 1 | $107 |
| AstraZeneca Pharmaceuticals LP | 1 | $68 |
| PFIZER INC. | 2 | $42 |
| GENZYME CORPORATION | 1 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: TREMFYA, Sucraid, MAVYRET, REZDIFFRA, ENTYVIO, IBSRELA, IMFINZI, RINVOQ.
Industry payments across MI — which companies pay providers there.
